Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JNJ-42041935 (HIF-PHD Inhibitor II) 是一种高效的,竞争性的、选择性的脯氨酰羟化酶PHD 抑制剂,抑制PHD1(pKi= 7.91±0.04),PHD2 (pKi= 7.29 ±0.05) 和 PHD3 (pKi= 7.65±0.09)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 348 | 现货 | ||
2 mg | ¥ 491 | 现货 | ||
5 mg | ¥ 823 | 现货 | ||
10 mg | ¥ 1,230 | 现货 | ||
25 mg | ¥ 2,260 | 现货 | ||
50 mg | ¥ 3,730 | 现货 | ||
100 mg | ¥ 5,450 | 现货 | ||
500 mg | ¥ 11,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 898 | 现货 |
产品描述 | JNJ-42041935 (HIF-PHD Inhibitor II) is a potent (pKi = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes. |
体外活性 | JNJ-42041935 is the most potent inhibitor of PHD2181–417 with a pIC50 value of 7.0±0.03. JNJ-42041935 also inhibits full-length PHD1, PHD2, and PHD3 enzymes (pKi values 7.91±0.04, 7.29 ±0.05, and 7.65±0.09, respectively) [1]. |
体内活性 | JNJ-42041935 is used to compare the effect of selective inhibition of PHD to intermittent, high doses (50 μg/kg i.p.) of an exogenous erythropoietin receptor agonist in an inflammation induced anemia model in rats. JNJ-42041935 (100 μmol/kg, once a day for 14 days) is effective in reversing inflammation-induced anemia while erythropoietin has no effect. Administration of JNJ-42041935 (100 μmol/kg p.o.) for 5 consecutive days resulted in a 2-fold increase in reticulocytes, an increase in hemoglobin by 2.3 g/dl, and an increase in the hematocrit of 9%. Two hours after oral administration of 300 μmol/kg JNJ-42041935, the bioluminescence over the peritoneal area is increased by 2.2 ± 0.3-fold relative to luciferase-treated vehicle controls in the mouse [1]. |
激酶实验 | The potency of JNJ-42041935 for inhibition of the structurally related enzyme FIH is assessed by methods similar to those described for PHD2. In brief, activity of FIH is determined using purified glutathione transferase-tagged full-length FIH amino acids 1 to 350 and a synthetic HIF-1α peptide corresponding to residues Asp788 to Leu822. Compounds are preincubated with 17.1 nM FIH for 30 min, followed by a 10-min incubation with 1 μM [2-14C]2-oxoglutarate, in the presence of 10 μM FeNH4SO4 in reaction buffer. The selectivity of JNJ-42041935 for inhibition of a range of other targets available for testing in commercial assays is also assessed at concentrations of 1 and 10 μM[1]. |
别名 | HIF-PHD Inhibitor II |
分子量 | 346.65 |
分子式 | C12H6ClF3N4O3 |
CAS No. | 1193383-09-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (144.24 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8848 mL | 14.4238 mL | 28.8475 mL | 72.1189 mL |
5 mM | 0.577 mL | 2.8848 mL | 5.7695 mL | 14.4238 mL | |
10 mM | 0.2885 mL | 1.4424 mL | 2.8848 mL | 7.2119 mL | |
20 mM | 0.1442 mL | 0.7212 mL | 1.4424 mL | 3.6059 mL | |
50 mM | 0.0577 mL | 0.2885 mL | 0.577 mL | 1.4424 mL | |
100 mM | 0.0288 mL | 0.1442 mL | 0.2885 mL | 0.7212 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
JNJ-42041935 1193383-09-3 Chromatin/Epigenetic Metabolism HIF/HIF Prolyl-Hydroxylase HIF-PH inhibit HIFs JNJ42041935 Inhibitor Hypoxia-inducible factors JNJ 42041935 HIF-PHD Inhibitor II inhibitor